About US
Contact us
-
Xellia Pharma buys former Boehringer Ben Venue plant, once the poster child of quality failingsDenmark's Xellia Pharmaceuticals has bought the formerBen Venueplant, at one time the most notorious U.S. plant underFDAsupervision, and the facility responsible for dozens of recalls and a slew of dr2015/11/27
-
FDA approves BMS' Opdivo for kidney cancer a week after granting priority reviewIn another striking FDA turnaround for Bristol-Myers Squibb's ($BMY)Opdivo, the agency has approved it for treating advanced renal cell carcinoma just a week after granting priority review. The agenc2015/11/24
-
With veteran job-choppers Pfizer and Allergan joining hands, how many layoffs are in the cards?Both Pfizer ($PFE) and Allergan ($ACT) have a history of doing "transformational" deals--and those can come along with serious layoffs. So now that they've joined hands in a $160 billion merger agreem2015/11/24
-
Takeda's Velcade successor gets quick FDA approvalJust a couple of months after accepting the application, theFDAhas approvedTakeda Pharmaceutical's Ninlaro, a treatment for multiple myeloma that the Japanese company hopes can get established before2015/11/23
-
Novartis snags new approvals for Cosentyx in EuropeNovartis ($NVS) has been jockeying for additional uses for its next-gen psoriasis med,Cosentyx, hoping that a trifecta of indications will help generate blockbuster sales and distinguish the drug from2015/11/23
-
Adapt's new bargain-priced OD antidote enters contentious marketThe rising number of opioid-related deaths in the U.S. has translated into big opportunity for pharmas selling the antidote med naloxone, with drugmakers such as Amphastar Pharmaceuticals ($AMPH) gett2015/11/20
-
Pfizer prepared to risk a 3% breakup fee for chance at Allergan, sources tell ReutersBreaking up can be hard to do. It can also be expensive, which would be the case for Pfizer if the roughly $150 billion deal it is reportedly negotiating with Allergan were to go south. But the potent2015/11/20
-
Big three PBMs cut loose more specialty pharmacies as scrutiny growsPharmacy benefit managershave broadened their crackdown on specialty pharmacies, with at least 8 cut off from reimbursement in recent days. The PBMs are targeting pharmacies with close ties to particu2015/11/17
-
History suggests a Pfizer-Allergan hookup would mean sizable cuts in manufacturingToday Pfizer ($PFE) has about 65 plants since picking upHospirain September. A hookup with Allergan ($AGN), which the two have acknowledged they are exploring, would add another 40. That inevitably le2015/11/17
-
Merck may appeal to Supreme Court after again losing fight to protect Cubicin patentsMerck & Co. ($MRK) is running low on options after a federal appeals court Thursday again declined to back four patents that would have held at bay for 5 more years generics of the antibioticCubic2015/11/16